Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

1.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24.

PMID:
25443274
[PubMed - in process]
2.

More accurate ways to measure tumor cellularity.

True LD.

Am J Clin Pathol. 2014 Dec;142(6):880. doi: 10.1309/AJCPGL9E3HCXFZTP. No abstract available.

PMID:
25389344
[PubMed - indexed for MEDLINE]
3.

Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors.

Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME.

Clin Cancer Res. 2014 Oct 15. [Epub ahead of print]

PMID:
25320358
[PubMed - as supplied by publisher]
4.

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.

J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.

PMID:
25311217
[PubMed - indexed for MEDLINE]
5.

Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.

Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, Comperat EM, Datta MW, Evans AG, Griffiths DF, Guo CC, Hailemariam S, Huang W, Humphrey PA, Jiang Z, Kahane H, Kristiansen G, La Rosa FG, Lopez-Beltran A, MacLennan GT, Magi-Galluzzi C, Merrimen J, Montironi R, Osunkoya AO, Picken MM, Rao N, Shah RB, Shanks JH, Shen SS, Tawfik OW, True LD, Van der Kwast T, Varma M, Wheeler TM, Zynger DL, Sahr N, Bostwick DG.

Ann Diagn Pathol. 2014 Dec;18(6):333-42. doi: 10.1016/j.anndiagpath.2014.08.010. Epub 2014 Sep 3.

PMID:
25263387
[PubMed - in process]
6.

Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.

Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS.

PLoS One. 2014 Sep 8;9(9):e104271. doi: 10.1371/journal.pone.0104271. eCollection 2014.

PMID:
25198178
[PubMed - in process]
Free PMC Article
7.

Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity.

Williamson SR, Cheng L, Eble JN, True LD, Gupta NS, Wang M, Zhang S, Grignon DJ.

Mod Pathol. 2015 Feb;28(2):279-94. doi: 10.1038/modpathol.2014.105. Epub 2014 Sep 5.

PMID:
25189644
[PubMed - in process]
8.

Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports.

Mossanen M, True LD, Wright JL, Vakar-Lopez F, Lavallee D, Gore JL.

Hum Pathol. 2014 Nov;45(11):2192-201. doi: 10.1016/j.humpath.2014.07.008. Epub 2014 Jul 25. Review.

PMID:
25149550
[PubMed - indexed for MEDLINE]
9.

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, Schneider EL, Craik C, Simon JA, Bedalov A, Nelson PS.

Cancer Discov. 2014 Nov;4(11):1310-25. doi: 10.1158/2159-8290.CD-13-1010. Epub 2014 Aug 13.

PMID:
25122198
[PubMed - in process]
10.

Readability of urologic pathology reports: the need for patient-centered approaches.

Mossanen M, Calvert JK, Wright JL, True LD, Lin DW, Gore JL.

Urol Oncol. 2014 Nov;32(8):1091-4. doi: 10.1016/j.urolonc.2014.04.011. Epub 2014 May 17.

PMID:
24846343
[PubMed - in process]
11.

Prognostic biomarkers: an introduction.

Bosman FT, True LD.

Virchows Arch. 2014 Mar;464(3):253-6. doi: 10.1007/s00428-014-1553-2. Epub 2014 Feb 22. No abstract available.

PMID:
24562304
[PubMed - indexed for MEDLINE]
12.

Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.

Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, Lin DW, Schmidt RA, Wright JL.

Am J Surg Pathol. 2014 Mar;38(3):333-8. doi: 10.1097/PAS.0000000000000162.

PMID:
24525503
[PubMed - indexed for MEDLINE]
13.

Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice.

True LD.

Virchows Arch. 2014 Mar;464(3):257-63. doi: 10.1007/s00428-013-1531-0. Epub 2014 Feb 1. Review.

PMID:
24487786
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B.

J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.

PMID:
24323034
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices.

Lee F, Gottsch H, Ellis WJ, True LD, Lin DW, Wright JL.

Adv Urol. 2013;2013:471234. doi: 10.1155/2013/471234. Epub 2013 Oct 24.

PMID:
24260032
[PubMed]
Free PMC Article
16.

Multicolor multicycle molecular profiling with quantum dots for single-cell analysis.

Zrazhevskiy P, True LD, Gao X.

Nat Protoc. 2013 Oct;8(10):1852-69. doi: 10.1038/nprot.2013.112. Epub 2013 Sep 5.

PMID:
24008381
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases.

Akfirat C, Zhang X, Ventura A, Berel D, Colangelo ME, Miranti CK, Krajewska M, Reed JC, Higano CS, True LD, Vessella RL, Morrissey C, Knudsen BS.

J Pathol. 2013 Jul;230(3):291-7. doi: 10.1002/path.4180.

PMID:
23420560
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Prostate cancer cell phenotypes based on AGR2 and CD10 expression.

Ho ME, Quek SI, True LD, Morrissey C, Corey E, Vessella RL, Dumpit R, Nelson PS, Maresh EL, Mah V, Alavi M, Kim SR, Bagryanova L, Horvath S, Chia D, Goodglick L, Liu AY.

Mod Pathol. 2013 Jun;26(6):849-59. doi: 10.1038/modpathol.2012.238. Epub 2013 Jan 25.

PMID:
23348903
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.

Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B, Corey E, Nelson PS, Vessella RL, Morrissey C.

Prostate. 2013 Jun;73(9):932-40. doi: 10.1002/pros.22639. Epub 2013 Jan 17.

PMID:
23334979
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.

Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD.

Adv Anat Pathol. 2013 Jan;20(1):39-44. doi: 10.1097/PAP.0b013e31827b665b. Review.

PMID:
23232570
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk